Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
Keywords: 99mTc-PYP, 99mTc-pyrophosphate; AF, atrial fibrillation; ATTR-CM, transthyretin amyloid cardiomyopathy; CMR, cardiac magnetic resonance; H/CL, heart to contralateral; HF, heart failure; LGE, late gadolinium enhancement; MCF, myocardial contraction fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SVI, stroke volume index; TTR, transthyretin; V122I, valine-122-isoleucine; amyloidosis; biomarkers; cardiac magnetic resonance; cardiomyopathy; eGFR, estimated glomerular filtration rate; echocardiography; nuclear imaging.
© 2019 The Authors.